速递｜刚刚，派格生物长效GLP-1新药维培那肽获批上市

Core Viewpoint - The article discusses the approval of Pegbio's innovative drug, Weipenaide injection, for improving blood glucose control in adults with type 2 diabetes, highlighting its efficacy, safety, and convenience in administration [4][6]. Drug Approval and Details - The National Medical Products Administration (NMPA) approved 129 applications, including Weipenaide injection, on November 12, 2025 [5]. - Weipenaide is a first-class innovative drug developed by Pegbio, utilizing polyethylene glycol modification of GLP-1 peptides to enhance bioactivity while reducing dosage [4]. Clinical Efficacy - Clinical trials show that after 24 weeks of treatment, HbA1c levels decreased by 1.37%, significantly outperforming the placebo group, with a cumulative reduction of 1.39% at 52 weeks [4]. - The drug demonstrated a rapid onset of action, with HbA1c dropping by 0.82% by the fourth week of treatment [6]. Weight Management and Additional Benefits - In patients with a BMI greater than 32 kg/m², the average weight loss after 52 weeks was 4.77 kg [6]. - Weipenaide also positively impacted cardiovascular risk factors, including blood pressure and lipid levels [6]. Safety Profile - The incidence of confirmed hypoglycemia was 0% over 26 weeks, with gastrointestinal adverse events being relatively low: nausea (8%), vomiting (5.1%), abdominal distension (5.1%), and diarrhea (7.3%) [6].